Drugs for reducing antibiotic resistance and killing bacteria

Betatides are novel synthetic cell-penetrating peptides that attack bacteria in a fundamentally new way. They reduce antibiotic resistance development and act as an antibiotic.

Treatment of skin, lung, prosthetic joint infections and other infections caused by drug-resistant bacteria.


  • Novel mode of action, new target (beta-clamp).
  • Broad single agent effects towards priority pathogens (all ESKAPE pathogens).
  • Potentiate effect of other antibiotics and no cross-resistance.
  • Reduce the development of resistance towards current and future antibiotics.
  • Successful studies in animal models of skin and prosthetic joint infection, successful pilot in lung infection.
  • Repeated dose toxicity study by i.v. infusion to rats showed no major toxic effects.


  • 1st generation betatides in preclinical stage, with patent granted in USA, Canada and several countries in Europe.
  • 2nd generation betatides under development.
  • Seeking commercial partners and licensees.